Featured Content

Winston Wong, PharmD
President, W-Squared Group

Drugmakers Turn Heat on Insurers by Backing Copay Limits

(Bloomberg) Mar 12, 2015 - The battle over soaring U.S. drug prices is heading for the states. With the price of some treatments topping $100,000, patient groups are pushing for state laws to make sure insurers cover most of the costs. Their campaign is backed by an important ally: the drug industry.

Commentary: While I am somewhat in agreement that copay should be limited at some level, I find the backing by the manufacturers...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

How Men Can Protect Against Cancer

(TIME) Mar 26, 2015 - It’s no surprise that being physically fit helps protect against heart disease, but a person’s level of fitness might also have a profound effect on cancer outcomes long before a diagnosis.
read article »

Healthcare Professionals Are Overmedicating Senior Cancer Patients, and Here's What Can Be Done

(Forbes) March 25, 2015 - Overmedicating senior cancer patients has become an area of concern for many in the medical community. Instead of strictly blaming healthcare professionals for their lack of oversight, experts point to the failures of available medication management tools.
read article »

Cancer Immunotherapy 'Has Entered Mainstream'

(Medscape Medical News) Mar 25, 2015 - Cancer immunotherapy takes centre stage in a series of articles about harnessing the immune system for therapy published March 25 as a special issue of Science Translational Medicine.
read article (free registration required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Drugmakers Turn Heat on Insurers by Backing Copay Limits (Bloomberg)

While I am somewhat in agreement that copay should be limited at some level, I find the backing by the manufacturers...posted by: Winston Wong, PharmD

ICD-10 Delay Soon Could be Back on Table (HealthData Management)

I have to wonder if ICD-10 will ever become a reality.posted by: Winston Wong, PharmD

Report: Specialty Drugs Drive Prescription Spending Jump (ABC News/Associated Press)

No doubt that specialty drug spending is driving higher trends. Hep C started the ball rolling faster, and anticipated...posted by: Winston Wong, PharmD

In Cancer Wars, It's Doctors vs. Hospitals (MedPage Today/HealthLeaders Media)

There truly is a huge disconnect in the system. Presently the system rewards more expensive care in the hospital...posted by: Thomas Marsland, MD

Bristol-Myers Hits 14-Year High as Cancer Drug’s Use Expands (Bloomberg)

The PD-1's are on a roll. We all have been watching this snowball's momentum grow and grow. We just need to figure...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Bayer has posted 6 new jobs.

Check out the OBR Job Board here.



Sponsored Content


Colon Cancer Awareness

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide. Kantar Health's new interactive colorectal cancer (CRC) infographic highlights the unmatched global reach of oncology data from our best-in-class data sources. The infographic captures data from Japan, Germany, China, Brazil and the U.S. - a small sample of our global capabilities.

View Infographic >>




COA_AnnualConf_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
BPTH +4.19%
LOXO +3.23%
CYTK +3.21%
BIND -8.00%
KITE -7.32%
RDHL -5.88%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: March 2015
Company: Nektar Therapeutics
Product: NKTR-102

Date: Q1 2015
Company: Cell Therapeutics
Product: pacritinib

Date: Q2 2015
Company: Exelixis
Product: cabozantinib

See All OBR Radar items»